Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03448874
Other study ID # DLG-072-06
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date April 2018
Est. completion date July 2019

Study information

Verified date July 2020
Source Sealantis Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate safety of Seal-G MIST System in reinforcing colorectal anastomosis, in subjects undergoing colorectal surgery.


Description:

Study procedures:

Pre-surgery:

- Screening will be performed among adult subjects who are scheduled for an elective colorectal surgery. Once potential eligibility to the study is determined based on the study's inclusion/exclusion criteria, study procedures will be explained to the candidate and participation will be offered.

- Informed consent process.

- Pre-surgery assessments will be according to the routine practice at the site and determined by the treating physician.

Intra-operative:

- During the surgery, after confirmation of the intra-operative exclusion criteria, completion of anastomosis creation and only after leak test was performed , subjects will be allocated to one of the two treatment arms with a 1:1 ratio based on a randomization scheme (either to the Standard of care (SOC) or to Seal-G MIST arms).

- Device (Seal-G MIST System) application (to Seal-G MIST treatment arm only).

Post-operative follow-up:

- Subjects will be followed during post-operative period until discharge from the hospital for clinical and subclinical leaks according to the SOC.

- In an event of suspected anastomotic leak, patient will be treated according to severity of leak and PI clinical judgement (conservative treatment, drainage, diversion, anastomosis take down).

- Subjects will be followed up for leaks and related AE/SAEs at the day of the surgery and for a period of 15 weeks (±2 weeks) post-surgery, including the following activities:

- Daily while hospitalized (in accordance with the site routine procedures)

- At 1 month (±1 week) and 15 weeks (±2 weeks) post-surgery (Hospitalization for elective procedure (i.e. chemotherapy treatments) will not be considered as SAEs)


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date July 2019
Est. primary completion date April 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject >18 years

2. Subject is scheduled for elective open or laparoscopic colorectal resection (including left colectomy, sigmoidectomy, anterior resection, subtotal colectomy) surgery (including robotic) involving the creation of circular stapler anastomosis

3. Subject signs and dates a written Informed Consent Form, indicates an understanding of the study procedures and follow-up requirements and is willing to comply with them

Exclusion Criteria:

1. Anastomosis is expected to be = 10cm from anal verge

2. Surgery involves stoma creation

3. Subject who underwent a prior pelvic radiation therapy

4. Subject with a BMI > 40 or <19

5. Subject with American Society of Anesthesiologists (ASA) status higher than 3

6. Albumin level < 3 gr/dl

7. Hemoglobin level < 8 g/dl on day of surgery

8. Subject has a diagnosis of bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischemic bowel, and carcinomatosis

9. Subject treated with immunosuppressive agents within 28 days prior to study enrollment (including corticosteroids)

10. Serious or uncontrolled co-existent diseases (e.g. severe cardiovascular disease, congestive heart failure, recent myocardial infarction within 6 months from surgery, significant vascular disease, active or uncontrolled autoimmune disease, active or uncontrolled infection, uncontrolled diabetes mellitus with episodes of hospitalization due to hypo or hyperglycemia within 6 months of surgery)

11. Subject known to have distant metastases, such as liver, lung, bone etc. metastases (not including local and regional lymph nodes)

12. Subject with known sensitivity to Indigo carmine dye (E132)

13. Subject who according to the investigator clinical judgement is not suitable for participation in the study

14. Subject with a life expectancy of less than 1 year

15. Subject requires more than one anastomosis during the surgery

16. Subject is scheduled for another surgery during the follow up period of this study

17. Subject participating in any other study involving an investigational (unapproved) drug or device

18. Woman who is known to be pregnant or breast-feeding or woman who is planning pregnancy or breast-feeding in the 5 next months

19. Vulnerable subjects (e.g. mentally handicapped, prisoners, etc.)

Study Design


Intervention

Device:
Seal-G MIST System
Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sealantis Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of overall subject pre-specified* procedure related Adverse Events Pre-specified procedure related Adverse Event: Wound infection; Bowel obstruction and Post-operative ileus; Anastomotic stricture; Anastomotic leak; Collection/Abscess; Urinary retention/Urinary Tract Infection; Renal failure; Hepatic failure; Peritoneal metastasis; Staple-line bleeding; Allergic reaction; Re-intervention (Including but not limited to re-operation; stoma). up to 15 weeks (±2 weeks) post-surgery
Secondary Incidence of clinical anastomotic leaks Anastomotic leak (AL) is defined as evidence of a defect in the intestinal wall integrity at the anastomotic site leading to local or general peritonitis, abscesses in the proximity of the anastomosis and/or fistula, fecal or purulent discharge from drains. up to 15 weeks (±2 weeks) post-surgery
Secondary Incidence of subclinical/ radiological leaks As assessed from Adverse event/Serious Adverse Event reporting form up to 15 weeks (±2 weeks) post-surgery
Secondary Incidence of Serious Adverse Events (SAE) complications According to Serious Adverse Event (SAE) definition from Medical Device Directive (MEDDEV 2.7/3, Rev 3, May 2015) up to 15 weeks (±2 weeks) post-surgery
Secondary Incidence of collection/abscess without demonstrated leak According to Adverse event reporting form up to 15 weeks (±2 weeks) post-surgery
Secondary Incidence of reoperation According to Adverse event/Serious Adverse Event reporting form up to 30 days post-surgery
Secondary Incidence of postoperative mortality up to 15 weeks (±2 weeks)
Secondary Hospital length of stay From date of surgery until the time for "Ready to be discharged" (in days), an average of 10±4 days
Secondary Incidence of "deployment failure" only for treatment arm during surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A